160 related articles for article (PubMed ID: 31107373)
1. The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population.
Poulussen FCP; Peters BJ; Hua KH; Houthuizen P; Grouls RJ; Deenen MJ
Pharmacogenet Genomics; 2019 Sep; 29(7):179-182. PubMed ID: 31107373
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
3. Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.
Anstensrud AK; Molden E; Haug HJ; Qazi R; Muriq H; Fosshaug LE; Spigset O; Øie E
Eur J Clin Pharmacol; 2020 May; 76(5):673-683. PubMed ID: 31940084
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.
Goryachkina K; Burbello A; Boldueva S; Babak S; Bergman U; Bertilsson L
Eur J Clin Pharmacol; 2008 Dec; 64(12):1163-73. PubMed ID: 18648788
[TBL] [Abstract][Full Text] [Related]
6. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
[TBL] [Abstract][Full Text] [Related]
8. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
9. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
10. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
11. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.
Seeringer A; Brockmöller J; Bauer S; Kirchheiner J
Eur J Clin Pharmacol; 2008 Sep; 64(9):883-8. PubMed ID: 18545991
[TBL] [Abstract][Full Text] [Related]
12. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.
Ismail R; Teh LK
J Clin Pharm Ther; 2006 Feb; 31(1):99-109. PubMed ID: 16476126
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
[TBL] [Abstract][Full Text] [Related]
14. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.
Rau T; Wuttke H; Michels LM; Werner U; Bergmann K; Kreft M; Fromm MF; Eschenhagen T
Clin Pharmacol Ther; 2009 Mar; 85(3):269-72. PubMed ID: 19037197
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
[TBL] [Abstract][Full Text] [Related]
16. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
[TBL] [Abstract][Full Text] [Related]
17. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
Bijl MJ; Visser LE; Hofman A; Vulto AG; van Gelder T; Stricker BH; van Schaik RH
Br J Clin Pharmacol; 2008 Apr; 65(4):558-64. PubMed ID: 18070221
[TBL] [Abstract][Full Text] [Related]
18. The relationship between plasma concentration of metoprolol and CYP2D6 genotype in patients with ischemic heart disease.
Wojtczak A; Wojtczak M; Skrętkowicz J
Pharmacol Rep; 2014 Jun; 66(3):511-4. PubMed ID: 24905532
[TBL] [Abstract][Full Text] [Related]
19. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
[TBL] [Abstract][Full Text] [Related]
20. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.
Rau T; Heide R; Bergmann K; Wuttke H; Werner U; Feifel N; Eschenhagen T
Pharmacogenetics; 2002 Aug; 12(6):465-72. PubMed ID: 12172215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]